1 May 2026Oral drugs
Dihydroartemisinin/Piperaquine = DHA/PPQ oral
Dihydroartemisinin and piperaquine guidance for uncomplicated malaria and post-parenteral completion therapy, with weight-based 3-day dosing.
Prescription under medical supervision
This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.
Therapeutic action
Antimalarial.
Indications
- Treatment of uncomplicated falciparum malaria.
- Treatment of uncomplicated malaria due to other Plasmodium species when chloroquine cannot be used.
- Completion treatment following parenteral therapy for severe malaria.
Forms and strengths
Co-formulated tablets of dihydroartemisinin and piperaquine in blister packs for a complete treatment for one individual.
There are 5 different blister packs.
- 20 mg DHA/160 mg PPQ tablets, blister pack of 3 tablets.
- 40 mg DHA/320 mg PPQ tablets, blister pack of 3 tablets.
- 40 mg DHA/320 mg PPQ tablets, blister pack of 6 tablets.
- 40 mg DHA/320 mg PPQ tablets, blister pack of 9 tablets.
- 40 mg DHA/320 mg PPQ tablets, blister pack of 12 tablets.
Dose and duration
Child 5 to < 25 kg: 2.5 to 10 mg/kg daily of DHA and 20 to 32 mg/kg daily of PPQ.
Child 25 kg and over and adult: 2 to 10 mg/kg daily of DHA and 16 to 27 mg/kg daily of PPQ.
Tablets are to be taken once daily for 3 days.
Weight-based dosing
- 5 to < 8 kg: 1 tablet of 20 mg/160 mg.
- 8 to < 11 kg: 1 1/2 tablets of 20 mg/160 mg.
- 11 to < 17 kg: 1 tablet of 40 mg/320 mg.
- 17 to < 25 kg: 1 1/2 tablets of 40 mg/320 mg.
- 25 to < 36 kg: 2 tablets of 40 mg/320 mg.
- 36 to < 60 kg: 3 tablets of 40 mg/320 mg.
- 60 to < 80 kg: 4 tablets of 40 mg/320 mg.
- >= 80 kg: 5 tablets of 40 mg/320 mg.
Contra-indications, adverse effects, precautions
- Do not administer in the event of cardiac disorders such as bradycardia, heart rhythm disorders, or congestive heart failure.
- Do not combine with drugs that prolong the QT interval such as amiodarone, other antimalarials, antipsychotics, fluconazole, fluoroquinolones, hydroxyzine, macrolides, and ondansetron.
- Administer with caution to patients over 60 years or with renal or hepatic impairment.
- May cause cardiac disorders including QT prolongation and tachycardia; rarely gastrointestinal disturbances, pruritus, hepatic disorders, and joint and muscle pain.
- Monitor combination with antiretrovirals and enzyme inducers such as rifampicin, carbamazepine, phenytoin, and phenobarbital.
- If the patient vomits within 30 minutes after administration, re-administer the full dose.
- If the patient vomits between 30 minutes and 1 hour after administration, re-administer half of the dose.
- Pregnancy: no contra-indication.
- Breast-feeding: no contra-indication.
Dosage and duration
| Weight | 20 mg/160 mg tablet | 40 mg/320 mg tablet |
|---|---|---|
| 5 to < 8 kg | 1 tab | - |
| 8 to < 11 kg | 1½ tab | - |
| 11 to < 17 kg | - | 1 tab |
| 17 to < 25 kg | - | 1½ tab |
| 25 to < 36 kg | - | 2 tab |
| 36 to < 60 kg | - | 3 tab |
| 60 to < 80 kg | - | 4 tab |
| ≥ 80 kg | - | 5 tab |
Source
MSF Essential drugs practical guidelines (January 2026)
This page reproduces the structured reference information for this batch while leaving out the Storage and Remarks sections.
Rate this guide
Be the first to rate this guide.